Skip to content
AnalystLens

Somnigroup International Annual Report, Year Ended Dec 31, 2009

Filing Date
Filed February 8, 2010
Period End
December 31, 2009
Security
SGI
One revenue dollarkept$0.10
In the record · 2016–202610-K1110-Q328-K220

SGI filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 220 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’17Jun ’17
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Sep ’25Sep ’25

Summary

Summary of the 10-K filed February 8, 2010. Cited figures are marked; the original filing is the authoritative source.

Tempur-Pedic International Inc. (filed under this name; now Somnigroup International, SGI) reported net sales of $831.2 milliona for the year ended December 31, 2009, down from $927.8 million in 2008 and $1,106.7 million in 2007.

Net income rose to $85.0 millionb, or $1.12 per diluted share, from $58.9 million, or $0.79, in 2008. Gross profit margin improved to 47.4% from 43.2%, and operating income margin rose to 17.4% from 14.4%. The company attributed the top-line decline primarily to a weak U.S. macroeconomic environment that reduced consumer traffic and demand, with Domestic net sales down 8.0% and International net sales down 14.4%.

The balance sheet and cash generation improved meaningfully. Total debt was reduced by $121.9 million to $297.5 millionc at year-end, and the Funded debt to EBITDA ratio was 1.68 times against a covenant maximum of 3.0 times. Operating cash flow was $135.0 million, and capital expenditures were $14.3 million.

The company suspended its dividend in late 2008 to pay down debt and did not repurchase shares in 2008 or 2009. On January 13, 2010, the Board approved a new share repurchase program of up to $100.0 milliond, which replaces the October 2007 authorization. Key risks include an antitrust class action (Jacobs v.

Tempur-Pedic) that the company says it cannot predict the outcome of, a New York Attorney General inquiry into its unilateral retail price policy, and a pending Danish tax assessment of approximately $39.3 million including interest and penalties. The filing also discloses concentration risk, with the top five customers accounting for 18.9% of 2009 net sales, and leverage of $297.5 million in long-term debt against stockholders' equity of $172.3 million.

Key Highlights

  1. Net sales fell 10.4% to $831.2 million in 2009 from $927.8 million in 2008, driven mainly by lower Domestic Retail mattress sales in a weak U.S. economy.
  2. Net income increased to $85.0 million ($1.12 diluted EPS) from $58.9 million ($0.79 diluted EPS), helped by the absence of the 2008 $11.6 million repatriation tax charge.
  3. Gross profit margin expanded to 47.4% from 43.2%, and operating income margin rose to 17.4% from 14.4%.
  4. Total debt was reduced by $121.9 million to $297.5 million; Funded debt to EBITDA was 1.68 times versus a 3.0 times covenant maximum.
  5. Operating cash flow was $135.0 million in 2009, versus $198.4 million in 2008, with capital expenditures of $14.3 million.
  6. A new $100.0 million share repurchase authorization was approved on January 13, 2010, and the dividend suspended in late 2008 remains suspended.
  7. Principal legal and tax exposures include the Jacobs antitrust class action, a New York Attorney General inquiry into the unilateral retail price policy, and a Danish tax assessment of approximately $39.3 million.

Follow one dollar

Of each $1.00 of revenue in FY2009, Somnigroup International kept $0.10.

  1. Revenue$831.2M100.0%
  2. Cost of revenue−$437.4M52.6%
  3. Gross profit$393.7M47.4%
  4. Operating costs−$248.8M29.9%
  5. Operating income$144.9M17.4%
  6. Interest, other & tax−$60.0M7.2%
  7. Net income$85.0M10.2%
Computed from 10-KFY2009filed February 8, 2010Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2009 revenue went

$831.2M
  • Cost of revenue: $437.4M, 53% of revenue
  • Other operating costs: $242.3M, 29% of revenue
  • Net income: $85.0M, 10% of revenue
  • R&D: $6.5M, 0.8% of revenue
  • Interest, other & tax: $60.0M, 7.2% of revenue

Kept 10% as net incomeR&D $6.5M · 0.8%

Full revenue history →

Financial Statements

FY2009 against FY2008

Line itemFY2009FY2008Change
Revenue$831.16M$927.82M−10.4%
Cost of Revenue$437.41M$526.86M−17.0%
Gross Profit$393.74M$400.96M−1.8%
R&D Expenses$6.46M——
Operating Income$144.94M$133.86M+8.3%
Interest Expense$17.35M$25.12M−30.9%
Net Income$84.99M$58.87M+44.4%
EPS (Basic)$1.13$0.79+43.0%
EPS (Diluted)$1.12$0.79+41.8%
Shares Outstanding (Basic)74.93M74.74M+0.3%
Shares Outstanding (Diluted)76.05M74.91M+1.5%

Frequently Asked Questions

  1. How did revenue and profitability change in 2009?

    Net sales declined to $831.2 million from $927.8 million, with Domestic sales down $45.4 million and International sales down $51.3 million. Despite the lower sales, net income rose to $84,993 thousand from $58,868 thousand, because 2008 included an $11.6 million tax provision tied to repatriating foreign earnings and because gross margin improved to 47.4%.

  2. How much debt does the company carry and is it within covenants?

    Total debt was $297.5 million at December 31, 2009, down from $419.3 million a year earlier. The Funded debt to EBITDA ratio was 1.68 times, within the 2005 Senior Credit Facility covenant requiring no more than 3.0 times. The company states it was in compliance with all covenants at year-end.

  3. Is the company paying dividends or buying back stock?

    No dividends were paid in 2009, and the quarterly dividend was suspended in October 2008 to redirect funds to debt reduction. No shares were repurchased in 2008 or 2009. On January 13, 2010, the Board authorized a repurchase of up to $100.0 million of common stock, replacing the October 2007 authorization, though the filing notes the program may be suspended or terminated at any time.

  4. What are the main legal and tax risks disclosed?

    The company faces the Jacobs antitrust class action over Tempur-Pedic mattress pricing, which the company says it strongly believes lacks merit but for which it cannot predict the outcome or estimate a loss range. The New York Attorney General's Antitrust Bureau has also asked the company to discontinue its unilateral retail price policy and may bring an enforcement action. A Danish tax assessment of approximately $39.3 million including interest and penalties is pending, with the IRS expected to finalize its position on the Bilateral APA by the second quarter of 2010.

  5. How concentrated is the customer base and what channels drive sales?

    The top five customers accounted for 18.9% of 2009 net sales. Retail was the largest channel at 84.5% of net sales, followed by Direct at 6.0%, Healthcare at 4.3%, and Third party at 5.2%. The filing notes that many customer arrangements are by purchase order or terminable at will.